Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Hang Yang, Xinyi Zhou, Dongliang Fu, et al.
Cancer Communications (2022) Vol. 43, Iss. 1, pp. 42-74
Open Access | Times Cited: 20

Showing 20 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 148
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Lala S. Rathod, Pratap S. Dabhade, Santosh N. Mokale
Drug Discovery Today (2023) Vol. 28, Iss. 5, pp. 103557-103557
Closed Access | Times Cited: 19
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor
Yan Lv, Zixuan Yang, Yiming Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2487-2511
Closed Access | Times Cited: 6
Genomic characterization of thymic epithelial tumors in a real-world dataset
Ken Kurokawa, Takehito Shukuya, R.A. Greenstein, et al.
ESMO Open (2023) Vol. 8, Iss. 5, pp. 101627-101627
Open Access | Times Cited: 16
Innovative PNA-LB mediated allele-specific LAMP for KRAS mutation profiling on a compact lab-on-a-disc device
Maryam Sadat Mirlohi, Esmail Pishbin, Rasool Dezhkam, et al.
Talanta (2024) Vol. 276, pp. 126224-126224
Closed Access | Times Cited: 5
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial
Zixian Wang, Junjie Peng, Xinjun Liang, et al.
Med (2024) Vol. 5, Iss. 9, pp. 1150-1163.e3
Closed Access | Times Cited: 4
An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review
Ahmed Sabt, Haytham O. Tawfik, Eman F. Khaleel, et al.
Molecular Diversity (2024)
Closed Access | Times Cited: 3
Hexavalent chromium [Cr(VI)]-induced ribosomal DNA copy number variation and DNA damage responses and their associations with nucleolar protein HRAS in humans and cells
Huadong Xu, Li Shi, Lingfang Feng, et al.
Environmental Pollution (2023) Vol. 331, pp. 121816-121816
Closed Access | Times Cited: 8
Impact of protein corona and PEGylation on the accumulation and efficacy of lysosome-disrupting lipid nanoparticles in KRAS-mutated cancer
Hangsheng Yang, Jiafeng Wang, Xinyi Zhou, et al.
Nano Today (2024) Vol. 56, pp. 102307-102307
Closed Access | Times Cited: 2
Protein tyrosine phosphatases: emerging role in cancer therapy resistance
Min Zhao, Shuai Wen, Zehao Su, et al.
Cancer Communications (2024) Vol. 44, Iss. 6, pp. 637-653
Open Access | Times Cited: 2
Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells
Naushin L. Hindul, Lauren R. Abbott, Sumaya M D Adan, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 6, pp. 107409-107409
Open Access | Times Cited: 1
Exploring the landscape of post-translational modification in drug discovery
Yuhao Cao, Tianyi Yu, Zhiguang Zhu, et al.
Pharmacology & Therapeutics (2024) Vol. 265, pp. 108749-108749
Closed Access | Times Cited: 1
Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer
Desh Deepak Singh, Shafiul Haque, Youngsun Kim, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 10, pp. 1336-1337
Open Access | Times Cited: 1
Advancing RAS inhibition: broad-spectrum targeting and tumor-selective activity of RMC-7977 in cancer therapy
Qunli Xiong, Yaguang Zhang
Science China Life Sciences (2024)
Closed Access
Crosstalk between metabolic and epigenetic modifications during cell carcinogenesis
Yue Gao, Shanpeng Zhang, Xianhong Zhang, et al.
iScience (2024) Vol. 27, Iss. 12, pp. 111359-111359
Open Access
Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells
Naushin L. Hindul, Lauren R. Abbott, Sumaya M.D. Adan, et al.
(2023)
Open Access
8-Aza Quinazolines as Brain Penetrant SOS1 Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 11, pp. 1487-1488
Closed Access
Page 1

Scroll to top